Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

People taking the drugs had a lower risk of organ failure and death However, the drugs were associated with an increased risk ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Folks who took one of the latter class of drugs were 16% less likely to die, 10% less likely to need hospital care and 36% less apt to see their kidney disease progress, compared to patients ...

Over the two-year study, Zhang's team followed the medical records of 64,705 veterans with diabetes and chronic kidney disease, half of whom took a DPP4i medication and half of whom took a GLP1-RA.

GLP-1 receptor agonists were associated with better graft and patient survival. Clinical trials are needed to confirm these findings.

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease ... risks of GLP-1 weight-loss drugs ...